Alebund completes enrollment in Phase III AP301 trial

Version 1

Alebund Pharmaceuticals said it has completed patient enrollment in RESPOND-2, its global Phase III pivotal trial of AP301 for hyperphosphatemia in people with chronic kidney disease on maintenance dialysis. The company described AP301 as a novel fiber-iron-based phosphate binder and said the study, listed on ClinicalTrials.gov as NCT06933472, is a randomized, double-blind, multi-regional trial running in the U.S. and China. Alebund’s update follows earlier positive Phase III topline data from its China-focused RESPOND-1 study and a presentation of those results at ASN 2025, positioning RESPOND-2 as a key registrational step beyond China. (prnewswire.com)

Why it matters: While this is a human medicine development, it’s relevant to veterinary professionals tracking renal therapeutics, phosphate control strategies, and the broader kidney-disease pipeline. Hyperphosphatemia remains a major management issue in chronic kidney disease because poor phosphorus control is linked to CKD-mineral and bone disorder, vascular calcification, and worse outcomes, and the field continues to look for options with lower pill burden and better tolerability than older binders. AP301’s progress also shows continued commercial and clinical interest in phosphate management as companies compete with established binders and newer approaches such as tenapanor. (prnewswire.com)

What to watch: The next milestones are trial completion, topline RESPOND-2 data, and any regulatory filing plans Alebund outlines for markets beyond China. (prnewswire.com)